奧泰生物(688606.SH):2021年度淨利預增3.78%-17.05%
格隆匯1月14日丨奧泰生物(688606.SH)公佈2021年年度業績預增公吿,經財務部門初步測算,公司預計2021年年度實現歸屬於母公司所有者的淨利潤7.049億元至7.95億元,與上年同期(法定披露數據)相比,將增加2567.79萬元至1.158億元,同比增加3.78%至17.05%。
歸屬於母公司所有者扣除非經常性損益後的淨利潤6.866億元至7.767億元,與上年同期(法定披露數據)相比,將增加1417.12萬元至1.04億元,同比增加2.11%至15.51%。
業績變化的主要原因:2021年新冠疫情持續深入影響全球,公司持續提高產品質量,通過自身品牌影響力和產品良好的口碑,不斷深耕和開拓國際市場,因此新冠檢測業務保持穩定增長,促使公司2021年經營業績繼續呈現增長態勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.